Scholarlink

Background <p>The coexistence of heart failure (HF) and renal insufficiency, termed cardiorenal syndrome (CRS), significantly increases mortality in HF patients. Although gut microbiota-host metabolic interactions contribute to the pathology of both conditions, their regulatory mechanisms in CRS remain unclear.</p> Methods <p>This cross-sectional study enrolled 451&#xa0;subjects&#xa0;from two medical institutions across different regions of China, comprising 155 patients with CRS, 225 with HF alone, and 71 controls. Using integrated metabolomics and 16S rRNA sequencing, we compared 801 serum metabolites, 36,956 microbial amplicon sequence variants, and 14 clinical parameters across the three groups. Additionally, associations between serum metabolites, gut microbiota, and clinical parameters in the HF and CRS groups were analyzed.</p> Results <p>CRS patients had significantly higher serum uric acid, creatinine, and N-terminal pro-brain natriuretic peptide (NT-proBNP) levels, along with lower hemoglobin and albumin levels, compared with HF patients (<i>P</i> &lt; 0.05). Serum metabolomics identified 100 upregulated metabolites in CRS vs. HF (q-value &lt; 0.1), including endogenous metabolites (3-hydroxybutanoic acid, L-homocitrulline) and gut-derived uremic toxins (3-methyloxindole, p-cresol). Additionally, the CRS group showed significantly reduced gut microbiota α-diversity compared with HF and controls,&#xa0;along with a trend toward reduction in several taxa with key metabolic functions, including&#xa0;<i>Lachnospiraceae</i>,&#xa0;<i>Faecalibacterium</i>, and&#xa0;<i>Faecalibacterium_prausnitzii</i>. Moreover, these microbial abundances negatively correlated with endogenous or gut-derived metabolites, while metabolite levels positively correlated with cardiorenal function markers (NT-proBNP, creatinine).</p> Conclusion <p>This multi-omics study reveals a host-gut microbiota-metabolite association network in CRS, linking aberrant metabolites to microbiota dysbiosis and organ-toxic metabolite accumulation. These findings&#xa0;provide novel insights into CRS pathogenesis and&#xa0;potential&#xa0;targeted therapies.</p> Trial registration <p>Clinical trial number: ChiCTR2300071422.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Potential host-gut microbiota-metabolite associations in cardiorenal syndrome progression: a multi-omics integrative analysis

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年1月13日

查看全文
  • Chongyou Rao,
  • You Zhou,
  • Lifan Han,
  • Pei Li,
  • Aoyi Geng,
  • Qin Zhong,
  • Jian Zhou,
  • Kunlun He,
  • Feihu Zhou

摘要

Background

The coexistence of heart failure (HF) and renal insufficiency, termed cardiorenal syndrome (CRS), significantly increases mortality in HF patients. Although gut microbiota-host metabolic interactions contribute to the pathology of both conditions, their regulatory mechanisms in CRS remain unclear.

Methods

This cross-sectional study enrolled 451 subjects from two medical institutions across different regions of China, comprising 155 patients with CRS, 225 with HF alone, and 71 controls. Using integrated metabolomics and 16S rRNA sequencing, we compared 801 serum metabolites, 36,956 microbial amplicon sequence variants, and 14 clinical parameters across the three groups. Additionally, associations between serum metabolites, gut microbiota, and clinical parameters in the HF and CRS groups were analyzed.

Results

CRS patients had significantly higher serum uric acid, creatinine, and N-terminal pro-brain natriuretic peptide (NT-proBNP) levels, along with lower hemoglobin and albumin levels, compared with HF patients (P < 0.05). Serum metabolomics identified 100 upregulated metabolites in CRS vs. HF (q-value < 0.1), including endogenous metabolites (3-hydroxybutanoic acid, L-homocitrulline) and gut-derived uremic toxins (3-methyloxindole, p-cresol). Additionally, the CRS group showed significantly reduced gut microbiota α-diversity compared with HF and controls, along with a trend toward reduction in several taxa with key metabolic functions, including Lachnospiraceae, Faecalibacterium, and Faecalibacterium_prausnitzii. Moreover, these microbial abundances negatively correlated with endogenous or gut-derived metabolites, while metabolite levels positively correlated with cardiorenal function markers (NT-proBNP, creatinine).

Conclusion

This multi-omics study reveals a host-gut microbiota-metabolite association network in CRS, linking aberrant metabolites to microbiota dysbiosis and organ-toxic metabolite accumulation. These findings provide novel insights into CRS pathogenesis and potential targeted therapies.

Trial registration

Clinical trial number: ChiCTR2300071422.